Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

Plus: *Batman voice* "Where is he!"

April 5, 2024 Check out STAT+

Sponsored By

Why is it surprising when drug executives stay true to their word? And can neoantigen cancer vaccines work? We cover all that and more this week on "The Readout LOUD," STAT's biotech podcast. Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve's gene editing plans.  Listen Now Subscribe to the podcast to never miss an episode iTunes Google Spotify SoundCloud Podcast Addict TuneIn Visit the archive to see past episodes

---

---

Enjoying The Readout LOUD? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser